Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth

NCT07588243 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2026-02-19
Last updated
2026-09-02

Condition(s) studied

Androgenic Alopecia

Investigational drug(s) / intervention(s)

Low Level Laser Therapy

Low Level Laser Therapy: Study participants received a total of 6 low level laser therapy treatments on their scalp. The treatments occurred 2 weeks apart (+/- 3 days).

Study summary

The goal of this clinical study is to evaluate the efficacy and safety of the Ultra device for the treatment of hair regrowth by assessing the improvement of hair density and hair shaft diameter.

Eligibility

Sex
ALL
Min age
22 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * 22 - 70 years old * Is willing to undergo study device use. * Fitzpatrick skin type I-VI * Clinical diagnosis of androgenetic alopecia (Norwood-Hamilton II-V or Ludwig I-II) * Willing to avoid significant changes to hair (such as drastic haircuts and dying hair) during their involvement in the study. * Willing to maintain current diet and exercise routine throughout study duration. * Understands and accepts the study condition to not receive any other procedures to the treatment area or to undergo any procedures, take any medications, supplements, or partake in any other treatments indicated for hair growth throughout the length of the study. * Understands and accepts the study condition of and agrees that he or she is able to be present for all study visits. * Willing to comply with all requirements of the study and is able to provide written informed consent. Exclusion Criteria: * Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding, or planning a pregnancy during the study period. * Has a diagnosis of other forms of alopecia (e.g., scarring alopecia, alopecia areata) * Has recent use (within 6 months) of a systemic hair growth medications (e.g., oral finasteride). * Inconsistent use of vitamins that can affect hair growth - must have stabilized use for at least 6 months prior to first treatment. * Had previous treatment (such as laser or topical) to scalp within 6 months. * Has a malignant disease, cancer, or uncontrolled medical condition. * Has an impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications

Primary outcome measure(s)

  • Difference in the Change in Hair Density from Baseline vs 90-day Follow-up — From baseline (treatment 1) to the 90 day follow up after treatment 6.
    To evaluate the difference in the change in hair density at baseline vs 90 day follow up in a pre-determined measurement point in the treatment area as measured with a professional dermascope.

Trial sites (2)

FacilityCityRegionStatus
Dy Dermatology Glenview Illinois
Cynosure Lutronic Westford Massachusetts
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07588243 on ClinicalTrials.gov ↗ ← All trials in the USA